Despite the excellent tolerability attributed to the new dihydropyridines, namely with respect to the incidence of ankle edema [23, 24], it may be surprising that none of the patients developed edema with lercanidipine in this study. However, the combination of a CCB with a modulator of the RAS has been shown to reduce the incidence of such events, through a well established mechanism [21, 25]. Only

a single case of cough was reported in our study, and this was considered to be possibly related to enalapril as cough is a known adverse effect Smad inhibitor of ACEIs [26]. Cough was the most common adverse event observed in clinical trials of lercanidipine/enalapril FDC [21]. The incidence of peripheral edema with the FDC also appears to be low, with only 1.5 % of patients treated with lercanidipine/enalapril 10/20 mg for up to 52 weeks in clinical trials experiencing this adverse event [21]. 5 Conclusion Treatment with an FDC of

lercanidipine/enalapril (10/20 mg) for a mean of 2.88 months was associated with a significant reduction of SBP and DBP and an increase in the BP control rate from 10.2 Panobinostat mouse to 51.0 %, relative to baseline, a result achieved with a reduction in the number of drugs used. The lercanidipine/enalapril FDC was shown to effectively reduce BP, generally independently of age and sex, and

with an excellent safety profile. Acknowledgments This registry was funded by an operational grant from Jaba Recordati S.A., Portugal. Medical writing assistance was provided by Raewyn Poole, on behalf of inScience Communications, Springer Healthcare. This assistance was funded by Jaba Recordati S.A., Portugal. Authors’ conflict of interests João Maldonado declares that he has no conflict of interest. Telmo Pereira declares that he has no conflict of interest. Alfredo Tavares is an employee of Jaba Recordati S.A. Open AccessThis article Nintedanib (BIBF 1120) is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. Appendix: Participants in the CONCEPT Collaborative Group This registry is the result of the commitment and dedication of a group of 46 specialists with a particular interest in cardiovascular diseases, listed below.